Log in

Relevant bibliographies by topics / Alzheimer's disease in fiction

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Alzheimer's disease in fiction'

Author: Grafiati

Published: 4 June 2021

Last updated: 24 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Alzheimer's disease in fiction.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Alzheimer's disease in fiction"

1

Imbeault, Hélène, Nathalie Bier, Hélène Pigot, Lise Gagnon, Nicolas Marcotte, Tamas Fulop, and Sylvain Giroux. "Electronic organiser and Alzheimer's disease: Fact or fiction?" Neuropsychological Rehabilitation 24, no. 1 (December 23, 2013): 71–100. http://dx.doi.org/10.1080/09602011.2013.858641.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Wolf, Johannes, Carsten Jäger, Markus Morawski, Ingolf Lachmann, Peter Schönknecht, Thomas Mothes, and Thomas Arendt. "Tissue transglutaminase in Alzheimer's disease – facts and fiction: a reply to “Tissue transglutaminase is a biochemical marker for Alzheimer's disease”." Neurobiology of Aging 35, no. 4 (April 2014): e5-e9. http://dx.doi.org/10.1016/j.neurobiolaging.2013.09.042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Abner, Erin L., Richard J. Kryscio, Frederick A. Schmitt, Karen S. SantaCruz, Gregory A. Jicha, Yushun Lin, Janna M. Neltner, Charles D. Smith, Linda J. Van Eldik, and Peter T. Nelson. "“End-Stage” Neurofibrillary Tangle Pathology in Preclinical Alzheimer's Disease: Fact or Fiction?" Journal of Alzheimer's Disease 25, no. 3 (July 8, 2011): 445–53. http://dx.doi.org/10.3233/jad-2011-101980.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Orr, David MR. "Dementia and detectives: Alzheimer’s disease in crime fiction." Dementia 19, no. 3 (May 28, 2018): 560–73. http://dx.doi.org/10.1177/1471301218778398.

Full text

Abstract:

Fictional representations of dementia have burgeoned in recent years, and scholars have amply explored their double-edged capacity to promote tragic perspectives or normalising images of ‘living well’ with the condition. Yet to date, there has been only sparse consideration of the treatment afforded dementia within the genre of crime fiction. Focusing on two novels, Emma Healey’s Elizabeth is Missing and Alice LaPlante’s Turn of Mind, this article considers what it means in relation to the ethics of representation that these authors choose to cast as their amateur detective narrators women who have dementia. Analysing how their narrative portrayals frame the experience of living with dementia, it becomes apparent that features of the crime genre inflect the meanings conveyed. While aspects of the novels may reinforce problem-based discourses around dementia, in other respects they may spur meaningful reflection about it among the large readership of this genre.

APA, Harvard, Vancouver, ISO, and other styles

5

Tynan, Avril. "Play and Possibility." Narrative Works 9, no. 2 (April 19, 2021): 135–51. http://dx.doi.org/10.7202/1076529ar.

Full text

Abstract:

Cultural representations of Alzheimer’s disease typically focus on the social and emotional burdens felt by family and friends, diluting or excluding the experience of the sufferer. This article demonstrates how narrative fiction may help us to engage with the experiences of individuals with Alzheimer’s disease by imagining what it might be like to suffer from the disease ourselves. Demonstrating the humanized and subjective understanding of Alzheimer’s disease articulated in Olivia Rosenthal’s (2007) On n’est pas là pour disparaître [We’re Not Here to Disappear (2015)] this article also exposes the limitations of narrative fiction as a means of highlighting our own ignorance in the face of others’ experiences.

APA, Harvard, Vancouver, ISO, and other styles

6

Guidetti, Matteo, Alessandro Bertini, Francesco Pirone, Gessica Sala, Paola Signorelli, Carlo Ferrarese, Alberto Priori, and Tommaso Bocci. "Neuroprotection and Non-Invasive Brain Stimulation: Facts or Fiction?" International Journal of Molecular Sciences 23, no. 22 (November 9, 2022): 13775. http://dx.doi.org/10.3390/ijms232213775.

Full text

Abstract:

Non-Invasive Brain Stimulation (NIBS) techniques, such as transcranial Direct Current Stimulation (tDCS) and repetitive Magnetic Transcranial Stimulation (rTMS), are well-known non-pharmacological approaches to improve both motor and non-motor symptoms in patients with neurodegenerative disorders. Their use is of particular interest especially for the treatment of cognitive impairment in Alzheimer’s Disease (AD), as well as axial disturbances in Parkinson’s (PD), where conventional pharmacological therapies show very mild and short-lasting effects. However, their ability to interfere with disease progression over time is not well understood; recent evidence suggests that NIBS may have a neuroprotective effect, thus slowing disease progression and modulating the aggregation state of pathological proteins. In this narrative review, we gather current knowledge about neuroprotection and NIBS in neurodegenerative diseases (i.e., PD and AD), just mentioning the few results related to stroke. As further matter of debate, we discuss similarities and differences with Deep Brain Stimulation (DBS)—induced neuroprotective effects, and highlight possible future directions for ongoing clinical studies.

APA, Harvard, Vancouver, ISO, and other styles

7

Small, Gary W. "Living Better Longer Through Technology." International Psychogeriatrics 11, no. 1 (March 1999): 3–6. http://dx.doi.org/10.1017/s1041610299005542.

Full text

Abstract:

Not long ago, I saw a science fiction film with the premise that genetic, medical, and computer technology had excelled to the point that within a matter of seconds, any ordinary citizen could submit a minute skin or hair sample for DNA analysis, which would yield his or her future lifetime medical history within rather certain probabilities. In this future society, I could learn that my new-born grandson would have an 83% probability of a severe myocardial infarction by age 62 and that if he survived it, he had a 91% chance that his Alzheimer's disease (AD) would progress to the moderate level by age 78.

APA, Harvard, Vancouver, ISO, and other styles

8

MEDINA, RAQUEL. "Who speaks up for Inés Fonseca? Representing violence against vulnerable subjects and the ethics of care in fictional narrative about Alzheimer's disease:Ahora tocad música de baile(2004) by Andrés Barba." Ageing and Society 37, no. 7 (April 20, 2016): 1394–415. http://dx.doi.org/10.1017/s0144686x16000337.

Full text

Abstract:

ABSTRACTThis paper studies the 2004 Spanish fictional novel by Andrés Barba,Ahora tocad música de baile, one of the first cultural texts dealing entirely with Alzheimer's disease to appear in Spain. It argues that the significance of Barba's fictional novel rests on two important issues: the ethics of representation of violence against vulnerable subjects and the ethics of care. The paper analyses how these two issues allow Barba to create a story in which the verbal and physical abuse to which the person living with Alzheimer's disease is subjected places the reader, on the one hand, as voyeur/witness of the abuse; and, on the other, as interpreter, and ultimately judge, of the fine line that separates euthanasia, assisted suicide and murder. The open ending of the novel defers all ethical and moral judgement to the reader. It examines how the novel offers a monolithic perspective about Alzheimer's disease, in which care is presented as a burden. In fact, this study shows that the novel's multi-layered structure and polyphonic nature places the emphasis on stigmas, stereotypes and negative metaphors around Alzheimer's disease, as found in contemporary social discourses.

APA, Harvard, Vancouver, ISO, and other styles

9

Muellenbach, Joanne Marie. "The Role of Reading Classic Fiction in Book Groups for People with Dementia is Better Understood through Use of a Qualitative Feasibility Study." Evidence Based Library and Information Practice 13, no. 2 (June 5, 2018): 97–99. http://dx.doi.org/10.18438/eblip29417.

Full text

Abstract:

A Review of: Rimkeit, B.S. and Claridge, G. (2017). Peer reviewed: literary Alzheimer’s, a qualitative feasibility study of dementia-friendly book groups. New Zealand Library & Information Management Journal, 56(2), 14-22. https://figshare.com/articles/Literary_Alzheimer_s_A_qualitative_feasibility_study_of_dementia-friendly_book_groups/5715052/1 Abstract Objective – To explore how people living with dementia experience reading classic fiction in book groups and what benefits this intervention provides. Design – Qualitative feasibility study. Setting – Day centre within a care home in the North Island of New Zealand. Subjects – Eight participants with a medical diagnosis of dementia – four community dwellers who attend day centers, and four residents of a secure dementia unit in a care home. Methods – Investigators used surveys, focus groups, and interpretative phenomenological analysis (IPA), for ideographic analysis of the data. Main results – Following analysis of the focus book group data, three superordinate, with related subordinate, themes were found: 1) the participant as a lively reader. The participants shared childhood memories of reading and when they became adults, how they encouraged reading within the household and with their own children. Subordinate themes included: recall, liveliness of discussion, and interest in reading and book clubs; 2) the participant as guardian of the voice of Dickens. Participants believed that, when the language is simplified, the beauty and rich imagery of Dickens is lost. Subordinate themes included: oversimplifying “loses the voice of Dickens”, familiarity, and continued play on words; and 3) the participant as a discerning book reviewer. The participants offered a number of ‘dementia-friendly’ suggestions, including the use of memory aids and simplifying text. Subordinate themes were expressed as four recommendations: use cast of characters; illustrations pick up the energy of the story, but balance quantity with risk of being childish; the physical quality of the text and paper; and chunk quantity of text while keeping the style of the original author. The choice of using classic fiction that was already well known was validated by the participants, who had some preconceptions about Ebenezer Scrooge, and described him by using epithets such as mean, an old bastard, and ugly. The participants found the investigators’ adapted version to be oversimplified, as short excerpts of the original Dickens seemed to evoke emotional and aesthetic responses of appreciation. Therefore, when creating adaptations, it is important to preserve the beauty of the original writing as much as possible. Conclusion – This qualitative feasibility study has provided a better understanding of how people living with dementia experience classic fiction in shared book groups. For individuals with Alzheimer’s disease, language skills may be well-preserved until later in the disease course. For example, the focus group participants demonstrated an appreciation and command of language, as well as enthusiasm and excitement in the sharing of the original Dickens with others. They suggested the use of memory aids, such as including a cast of characters, and repeating the referent newly on each page. Participants also suggested that the adapted version be shortened, to use a large font, and to include plenty of pictures. The choice of using classic fiction was validated by the participants, as they found these tales comforting and familiar, particularly when they included such colorful characters as Ebenezer Scrooge. Finally, people living with dementia should be encouraged to enjoy books for the same reason other adults love to read – primarily for the creative process. Classic fiction may be adapted to enhance readability, but the adaptation must be done in a thoughtful manner. While memory deficits occur in Alzheimer’s disease, an appreciation of complex language may be preserved until the later disease stages.

APA, Harvard, Vancouver, ISO, and other styles

10

Serkowska, Hanna. "D. D. jak dreszcz demencji." Poznańskie Studia Polonistyczne. Seria Literacka, no. 34 (January 11, 2019): 41–62. http://dx.doi.org/10.14746/pspsl.2018.34.2.

Full text

Abstract:

The claim here is that cultural representations of dementia may benefit from the structure of crime fiction which appears therefore to be among the theme most suited genres. We do not know enough about the disease or its etiology (the “culprit” remains unknown), hence the situation of the sufferer befits that of enigma or suspense, fear or confusion, doubt and presumption, standardly deployed by detective stories. Crime fiction narratives underscore that which is at stake in dementia: the riddle of disappearing of the person affected, the puzzle of memory loss, the identity doubt which extends to the relative when he or she is not recognized by the sufferer. By turning to a detective genre, Alzheimer’s novel profits from the genre’s growing popularity, owing to the reading public’s demand for challenges enhancing “mind reading” competences and training predictive abilities. The latter are more in demand as neurocognitive standards of readers grow.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Alzheimer's disease in fiction"

1

Grekin, Emily M. "Blood from a Stone." Ohio University / OhioLINK, 2012. http://rave.ohiolink.edu/etdc/view?acc_num=ohiou1338412191.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Navaratnam, Dasakumar Selveraj. "Cholinesterases in Alzheimer's disease." Thesis, University of Oxford, 1990. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.306734.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Newman, Tracey Anne. "Ageing and Alzheimer's disease." Thesis, University of Southampton, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.246220.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Montacute, Rebecca. "Infection in Alzheimer's disease." Thesis, University of Manchester, 2017. https://www.research.manchester.ac.uk/portal/en/theses/infection-in-alzheimers-disease(a69fbf77-1455-4a78-a700-54815cad926d).html.

Full text

Abstract:

Infections are a common co-morbidity in Alzheimer's disease (AD), and evidence suggests that infections can exacerbate neuroinflammation and increase cognitive decline in AD patients. In AD, immune changes are observed both in the central nervous system (CNS) and in the rest of the body. However, only a few studies have investigated immune responses to infection in AD. Here, two extensively studied infections, Toxoplasma gondii (T. gondii) and Trichuris muris (T. muris) were used to investigate infection in AD. T. gondii is a protozoan parasite which is common globally, including in the developed world where AD cases are increasing dramatically. Infection with T. gondii starts in the gut, before becoming systemic and then infecting the CNS, where the parasite forms a chronic cyst infection. In contrast, T. muris is a nematode parasite, which remains localised to the gut. Notably, T. gondii is known to alter neuroinflammation and behaviour. T. gondii forms cysts preferentially in the areas of the brain commonly affected by AD, such as the hippocampus, which therefore makes it an interesting model to study co-morbidity. AD is often associated with advanced age. As we age, our immune system declines, and an important unanswered question is whether age impacts on the immune response to infection. This is of particular significance when considering chronic infections such as T. gondii, which require immune surveillance to prevent parasite recrudescence. Therefore, the aim of this thesis was to investigate infection in AD by determining: whether the immune response to an infection is altered in AD; whether the immune response to an infection in AD differs with age; what the effects of infection are on neuroinflammation, pathology and behaviour in AD; what are the effects of chronic infection with T. gondii. Immune responses to infection were altered in both the 3xTg-AD and the APP PS1 mouse models of AD, including increased inflammation and weight loss in AD mice following infection. Although older (eleven to twelve-month-old) 3xTg-AD mice showed some alterations in cytokine responses following infection, overall there were no major difference compared to younger (five to six-month-old) animals. Additionally, infection was found to alter neuroinflammation in both 3xTg-AD and APP PS1 mice, though differently. In 3xTg-AD mice, microglia activation increased following infection with T. gondii and T. muris, showing that infection did not need to be in the brain to alter neuroinflammation. In APP PS1 mice, a decrease in microglia activation occurred after infection with T. gondii, which was accompanied by an increase in IL-1alpha production and increased amyloid beta levels in APP PS1 mice following infection. However, no changes were found in behaviour following infection with T. gondii or T. muris in AD mouse models. Finally, chronic T. gondii infection was investigated in the TgF344-AD rat, which was established as a suitable AD model with both amyloid and tau pathology in which to study chronic infection. This work adds to a growing body of literature to suggest that infections are detrimental to AD patients, and that future measures to decrease morbidity could focus on further study of infections in AD, and the development of strategies to better prevent infections in AD patients.

APA, Harvard, Vancouver, ISO, and other styles

5

Zubair, Mohammed. "Metabolomics in Alzheimer's disease." Thesis, University of Manchester, 2013. https://www.research.manchester.ac.uk/portal/en/theses/metabolomics-in-alzheimers-disease(0872757b-d25a-4c43-bd52-915d4cad21c6).html.

Full text

Abstract:

Metabolites are a potentially useful source of detecting and identifying disease specific biomarkers. This thesis investigates the possibility of using metabolomics applications to detect Alzheimer’s disease associated metabolite peaks in patients and to detect longitudinal changes of the disease. Serum samples and clinical data were collected from 60 healthy controls and 60 Alzheimer’s disease patients (60 at baseline and 60 at 12 month follow-up). The metabolic fingerprinting of serum samples using the FT-IR lacked discriminatory power to discriminate Alzheimer’s disease and non-disease samples due to the similar magnitude of biological and analytical variation. The metabolic profiling of serum samples using the GC-ToF-MS did not reveal any significantly altered metabolite peaks between the Alzheimer’s disease and non-disease groups. Metabolic profiling of serum samples using the UPLC-LTQ/Orbitrap-MS operated in the positive ionisation mode did not reveal any significantly altered metabolite peaks between the disease and non-disease groups. Up to twelve metabolite peaks were significantly altered in the Alzheimer’s disease baseline and follow-up samples, indicating a potential association with disease progression. Metabolic profiling of serum samples using the UPLC-LTQ/Orbitrap-MS operated in the negative ionisation mode did not reveal any significantly altered metabolite peaks between Alzheimer’s disease and non-disease groups. Three metabolite peaks were significantly altered in the Alzheimer’s disease baseline and follow-up samples, indicating a potential association with disease progression. Metabolic profiling of serum samples with the UPLC-LTQ/Orbitrap-MS may potentially be used to detect disease and disease progression associated metabolite peaks. The metabolite peaks require identification followed by a validation experiment.

APA, Harvard, Vancouver, ISO, and other styles

6

Shie, Feng-Shiun. "Cholesterol and Alzheimer's disease /." Thesis, Connect to this title online; UW restricted, 2000. http://hdl.handle.net/1773/6604.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Hynd, Matthew. "Excitotoxic neurodegeneration in Alzheimer's disease /." [St. Lucia, Qld.], 2004. http://www.library.uq.edu.au/pdfserve.php?image=thesisabs/absthe18145.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Blom, Elin. "Genetic Studies of Alzheimer's Disease." Doctoral thesis, Uppsala universitet, Institutionen för folkhälso- och vårdvetenskap, 2008. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-9397.

Full text

Abstract:

Patients with Alzheimer's disease (AD) often have a family history of the disease, implicating genetics as a major risk factor. Three genes are currently known to cause familial early-onset AD (<65 years): the amyloid precursor protein (APP) and the presenilins (PSEN1 and PSEN2). For the much more common late-onset disease (>65 years), only the APOE gene has repeatedly been associated to AD, where the ε4 allele increases disease risk and decreases age at onset. As APOE ε4 only explains part of the total estimated disease risk, more genes are expected to contribute to AD. This thesis has focused on the study of genetic risk factors involved in AD. In the first study, we conducted a linkage analysis of six chromosomes previously implicated in AD in a collection of affected relative pairs from Sweden, the UK and the USA. An earlier described linkage peak on chromosome 10q21 could not be replicated in the current sample, while significant linkage was demonstrated to chromosome 19q13 where the APOE gene is located. The linkage to 19q13 was further analyzed in the second study, demonstrating no significant evidence of genes other than APOE contributing to this peak. In the third study, the prevalence of APP duplications, a recently reported cause of early-onset AD, was investigated. No APP duplications were identified in 141 Swedish and Finnish early-onset AD patients, implying that this is not a common disease mechanism in the Scandinavian population. In the fourth study, genes with altered mRNA levels in the brain of a transgenic AD mouse model (tgAPP-ArcSwe) were identified using microarray analysis. Differentially expressed genes were further analyzed in AD brain. Two genes from the Wnt signaling pathway, TCF7L2 and MYC, had significantly increased mRNA levels in both transgenic mice and in AD brains, implicating cell differentiation and possibly neurogenesis in AD.

APA, Harvard, Vancouver, ISO, and other styles

9

Bakerink, Ronda Ann. "Semantic memory in Alzheimer's Disease." Thesis, University of British Columbia, 1988. http://hdl.handle.net/2429/27795.

Full text

Abstract:

Alzheimer's Disease is characterized by a general decline in cognitive functioning. Although phonology are relatively unaffected, patients with Alzheimer's Disease have been reported to have deficits of semantic memory. Thirteen patients with dementia, five of whom had a confirmed diagnosis of dementia, participated in the study. The purpose of this investigation was to replicate a study performed by Mark Byrd (1984), using Alzheimer's Disease patients. Subjects were presented with category-word decision pairs, for which the task was to decide if the word was an exemplar of the category, and category-letter decision pairs for which the task was to generate an exemplar of the category beginning with the letter. The dependent variable was reaction time. Results indicated that Alzheimer's Disease patients and dementia patients had longer reaction times than a group of age-matched control subjects, and that the Alzheimer's Disease and dementia patients showed a pattern of responses similar to that of the control subjects. All groups showed longer reaction times for the generation trials than the decision trials. The results are consistent with the existence of a semantic memory deficit in Alzheimer's Disease, but other interpretations were discussed.
Medicine, Faculty of
Audiology and Speech Sciences, School of
Graduate

APA, Harvard, Vancouver, ISO, and other styles

10

Williams, Abigail J. "Cystatin C and Alzheimer's disease." Thesis, University of Sheffield, 2014. http://etheses.whiterose.ac.uk/8547/.

Full text

Abstract:

Aggregation of amyloid-β in Alzheimer's disease (AD) is modulated in the presence of other amyloidogenic proteins including human cystatin C (hCC), which directly protects neuronal cells from Aβ-induced toxicity and inhibits fibril formation. Determination of the relevant conformations of the interacting Aβ and hCC is a key step to uncovering the molecular mechanism of hCC's activity in AD. A system for the production of recombinant Aβ1-40 has been established and is described here. It is also shown that hCC readily produces stable oligomeric species upon incubation in aggregating conditions, a phenomenon that has not been observed for other members of the cystatin family. Novel structural differences between amyloid fibrils produced by hCC and cystatin B have also been identified using limited proteolysis, indicating that hCC does not retain a monomer-like fold within the fibril and that the N-terminal is disordered and not part of the fibril core. The work presented here shows that hCC inhibits fibril production by Aβ in a dose-dependent manner, instead promoting the production of amorphous aggregates and small assemblies, with 2:1 molar ratios of hCC to Aβ being required for complete inhibition. It is unclear if the assemblies observed are toxic protofibrils or an alternative non-toxic species. A comparison of the inhibitory activity of the monomeric and dimeric forms of hCC was carried out, and indicated that the active region could be the hydrophobic loop involved in protease inhibition. Characterisation of binding by NMR HSQC experiments revealed that no observable complex was being formed between monomeric Aβ and folded monomeric hCC. Taken together these results suggest that hCC is selectively binding to an oligomeric species of Aβ and trapping the peptide in a non-toxic state.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Alzheimer's disease in fiction"

1

Poulin, Jacques. My sister's blue eyes. Toronto: Cormorant Books, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

illustrator, Farnsworth Bill, ed. Grandpa's music: A story about Alzheimer's. New York, NY: AV² by Weigl, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

ill, Farnsworth Bill, ed. Grandpa's music: A story about Alzheimer's. Morton Grove, Ill: Albert Whitman, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Casey, Barbara. Grandma Jock & Christabelle. Nashville, Tenn: J.C. Winston Pub. Co., 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Duocastella, Pilar. Silla de anea: La propia vida borrada por el Alzheimer. Zaragoza [Spain]: Mira Editores, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

O lugar escuro: Uma história de senilidade e loucura. Rio de Janeiro, RJ: Objetiva, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Duocastella, Pilar. Dona i cadira. Barcelona: Edicions La Campana, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Mary, Redman, ed. Mum, alzheimer's and me: Staying alive. Mequon, WI: Caritas Communications, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Frantti, Ann. Grandma's cobwebs: A story for children about Alzheimer's disease. Clifton Park, N.Y: Dagney Pub., 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Kibbey, Marsha. My grammy. Minneapolis, Minn., USA: Carolrhoda Books, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Alzheimer's disease in fiction"

1

Gruener, Patrick. "Alzheimer’s Disease in American Fiction." In Beyond the Great Forgetting, 143–297. Berlin, Heidelberg: Springer Berlin Heidelberg, 2022. http://dx.doi.org/10.1007/978-3-662-66029-4_5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Hort, J., J. T. O'Brien, G. Gainotti, T. Pirttila, B. O. Popescu, I. Rektorova, S. Sorbi, and P. Scheltens. "Alzheimer's Disease." In European Handbook of Neurological Management, 269–82. Oxford, UK: Wiley-Blackwell, 2010. http://dx.doi.org/10.1002/9781444328394.ch16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Khan, Qurat ul Ain, and Neill R. Graff-Radford. "Alzheimer's Disease." In Neurodegeneration, 102–14. Oxford, UK: John Wiley & Sons, Ltd, 2017. http://dx.doi.org/10.1002/9781118661895.ch11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Mandell, Alan M., and Robert C. Green. "Alzheimer's Disease." In The Handbook of Alzheimer's Disease and Other Dementias, 1–91. Oxford, UK: Wiley-Blackwell, 2011. http://dx.doi.org/10.1002/9781444344110.ch1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Böning, Dieter, Michael I. Lindinger, Damian M. Bailey, Istvan Berczi, Kameljit Kalsi, José González-Alonso, David J. Dyck, et al. "Alzheimer's Disease." In Encyclopedia of Exercise Medicine in Health and Disease, 57. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-540-29807-6_2076.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Galvin, James E. "Alzheimer's Disease." In Pathy's Principles and Practice of Geriatric Medicine, 865–80. Chichester, UK: John Wiley & Sons, Ltd, 2012. http://dx.doi.org/10.1002/9781119952930.ch73.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Shigeta, Masahiro, and Akira Homma. "Alzheimer's Disease." In Handbook of Gerontology, 333–66. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2012. http://dx.doi.org/10.1002/9781118269640.ch13.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Salmon, David P. "Alzheimer's disease." In Encyclopedia of psychology, Vol. 1., 130–33. Washington: American Psychological Association, 2000. http://dx.doi.org/10.1037/10516-044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Werhane, Madeleine L., David P. Sheppard, Kathleen F. Pagulayan, Mark W. Bondi, and Lisa Delano-Wood. "Alzheimer's Disease." In A Handbook of Geriatric Neuropsychology, 9–37. 2nd ed. New York: Routledge, 2022. http://dx.doi.org/10.4324/9781003100058-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Murthy, Sree Prathap Mohana. "Alzheimer's Disease." In Get Through MRCPsych: Preparation for the CASC, Second edition, 108–12. 2nd ed. London: CRC Press, 2022. http://dx.doi.org/10.1201/9780429073007-27.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Alzheimer's disease in fiction"

1

Rumao, Priti, and Mamta Padole. "Alzheimer's Disease." In DSMLAI '21': International Conference on Data Science, Machine Learning and Artificial Intelligence. New York, NY, USA: ACM, 2021. http://dx.doi.org/10.1145/3484824.3484886.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Poland, Bradley W., Panayiotis Zagouras, Snehal Naik, Eric Fauman, Karl Richter, and Robert M. Peitzsch. "Alzheimer's disease target selection." In the First ACM International Conference. New York, New York, USA: ACM Press, 2010. http://dx.doi.org/10.1145/1854776.1854870.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Brown, Anne, Nicholas Polys, David Bevan, and Ayat Mohammed. "Insights into Alzheimer's Disease." In XSEDE16: Diversity, Big Data, and Science at Scale. New York, NY, USA: ACM, 2016. http://dx.doi.org/10.1145/2949550.2952773.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Mao, Wenlu. "Overview of Alzheimer's Disease." In ICBBE '20: 2020 7th International Conference on Biomedical and Bioinformatics Engineering. New York, NY, USA: ACM, 2020. http://dx.doi.org/10.1145/3444884.3444900.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Zender, P. Mike, and Keith A. Crutcher. "Visualizing Alzheimer's disease research." In ACM SIGGRAPH 2004 Educators program. New York, New York, USA: ACM Press, 2004. http://dx.doi.org/10.1145/1186107.1186135.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Zhao, Haozuo, Haitao Chu, Sicheng Zhou, Fang Yu, Xianghua Luo, and Rui Zhang. "Racial Disparities in Alzheimer's Disease and Alzheimer's Disease-Related Dementias from the Disease Progression Perspective." In 2022 IEEE 10th International Conference on Healthcare Informatics (ICHI). IEEE, 2022. http://dx.doi.org/10.1109/ichi54592.2022.00107.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Shoaip, Nora, Sherif Barakat, and Mohammed Elmogy. "Alzheimer's Disease Integrated Ontology (ADIO)." In 2019 14th International Conference on Computer Engineering and Systems (ICCES). IEEE, 2019. http://dx.doi.org/10.1109/icces48960.2019.9068176.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Bobkova, Natalia. "ALZHEIMER'S DISEASE: YESTERDAY, TODAY, TOMORROW." In XV International interdisciplinary congress "Neuroscience for Medicine and Psychology". LLC MAKS Press, 2019. http://dx.doi.org/10.29003/m647.sudak.ns2019-15/492-493.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Loureiro, J. A., B. Gomes, M. A. Coelho, Maria do Carmo Pereira, and S. Rocha. "Immunoliposomes for Alzheimer's disease therapy." In 2013 IEEE 3rd Portuguese Meeting in Bioengineering (ENBENG). IEEE, 2013. http://dx.doi.org/10.1109/enbeng.2013.6518392.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Bernstein, Hans-Gert, Heidrun Kirschke, Bernd Wiederanders, Riitta Rinne, and Ari Rinne. "ALZHEIMER'S DISEASE: A LYSOSOMAL DISORDER?" In IX World Congress of Psychiatry. WORLD SCIENTIFIC, 1994. http://dx.doi.org/10.1142/9789814440912_0018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Alzheimer's disease in fiction"

1

Mehegan, Laura. Alzheimer's Disease and Dementia Awareness Poll 2018. AARP Research, June 2018. http://dx.doi.org/10.26419/res.00232.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Chandra, Amitabh, Courtney Coile, and Corina Mommaerts. What Can Economics Say About Alzheimer's Disease? Cambridge, MA: National Bureau of Economic Research, August 2020. http://dx.doi.org/10.3386/w27760.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Mintzer, Jacobo E., D. L. Bachman, M. Stuckey, M. Ebeling, M. T. Wagner, W. J. Evans, V. Hirth, A. Walker, R. Joglekar, and W. Faison. A State-Wide Research Network for Alzheimer's Disease. Office of Scientific and Technical Information (OSTI), March 2014. http://dx.doi.org/10.2172/1123171.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Mehegan, Laura. Alzheimer's Disease and Dementia Awareness Poll 2018: Infographic. AARP Research, June 2018. http://dx.doi.org/10.26419/res.00232.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Pericak-Vance, Margaret A. Whole Exome Analysis of Early Onset Alzheimer's Disease. Fort Belvoir, VA: Defense Technical Information Center, April 2013. http://dx.doi.org/10.21236/ada602412.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Pericak-Vance, Margaret A. Whole Exome Analysis of Early Onset Alzheimer's Disease. Fort Belvoir, VA: Defense Technical Information Center, April 2014. http://dx.doi.org/10.21236/ada603027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Duncan, Marie. Alzheimer's Disease Caregivers: The Transition from Home Care to Formal Care. Portland State University Library, January 2000. http://dx.doi.org/10.15760/etd.3220.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Rostaminejad, Marzieh. Stem Cell-based Therapies as a Promising Approach in Alzheimer's Disease. Peeref, July 2022. http://dx.doi.org/10.54985/peeref.2207p3321545.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Rostaminejad, Marzieh. Early Diagnosis of Alzheimer's disease using Electrochemical-based Nanobiosensors for miRNA Detection. Peeref, July 2022. http://dx.doi.org/10.54985/peeref.2207p6024343.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Bouranis, Nicole. Factors Affecting Clinical Research Enrollment Among Individuals with Alzheimer's Disease and Related Dementias. Portland State University Library, June 2020. http://dx.doi.org/10.15760/etd.7337.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!